Böblingen/Lódz – German pharmaceutical company Wörwag Pharma GmbH & Co. KG announces the acquisition of Sensilab, contract manufacturer and development service provider of pharmaceuticals, in Lódz, Poland. For the first time in the 50-year history, the family-owned company is investing in its own production facility - a decisive milestone for future growth.
„With the acquisition of this manufacturing company, we are laying an important foundation for our ambitious growth targets,” said Managing Director and CFO Gerhard Mayer. “Together with the Polish management team, we will develop the site into a Center of Excellence for oral dosage forms for the Wörwag Pharma Group.”
Wörwag Pharma is primarily investing in expanding its global product portfolio and opening up new markets. By acquiring Sensilab, the company secures the necessary production capacities to achieve these goals, in addition to its existing partnerships with suppliers. Furthermore, Wörwag will be able to ensure a reliable supply chain and provide customers with continuous access to high-quality products.
The modern production and development complex offers the opportunity to create additional capacity for further growth. The site is strategically located to supply core markets in Eastern Europe. In addition, Sensilab brings further expertise to the company, enabling the expansion of the product portfolio through the development of proprietary innovations.
About Sensilab
Sensilab is a contract manufacturer and development service provider for tablets, powders, granulates, and hard capsules. At its production site in Konstantynów Łódzki in the Lodz metropolitan area, Poland, 180 employees primarily serve customers across Europe. Sensilab was most recently part of the Polish USP Group.
